REFERENCES
- Katz H I, Prawer S E, Watson M J, et al. Mometasone furoate ointment 0.1% vs. hydrocortisone ointment 1.0% in psoriasis. Int J Dermatol 1989; 28: 342–4
- Medansky R S, Brody N I, Kanot N B, et al. Clinical investigations of mometasone furoate - a novel, nonfluorinated, topical corticosteroid. Semin Dermatol 1987; 6: 94–100
- Medansky R S, Bressinck R, Cole G W, et al. Mometasone furoate ointment and cream 0.1 per cent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 per cent and triamcinolone acetonide 0.1 per cent. Cutis 1988; 42: 480–5
- Rosenthal D, Duke E. A clinical investigation of the efficacy and safety of mometasone furoate ointment 0.1% vs betamethasone valerate ointment 0.1% in the treatment of psoriasis. Curr Ther Res 1988; 44: 790–801
- Svensson A, Reidhav I, Gisslén H, et al. A comparative study of mometasone furoate ointment and betamethasone valerate ointment in patients with psoriasis vulgaris. Curr Ther Res 1992; 52: 390–6
- Greaves M W, Weinstein G D. Treatment of psoriasis. N Engl J Med 1995; 332: 581–8
- Weirich E G. Dermatopharmacology of salicylic acid. I. Range of dermatotherapeutic effects of salicylic acid. Dermatologica 1975; 151: 268–73
- Krochmal L, Wang J CT, Patel B, Rodgers J. Topical corticosteroid compounding: effects on physicochemical stability and skin penetration rate. J Am Acad Dermatol 1989; 21: 979–84
- Elie R, Durocher L P, Kavalec E C. Effect of salicylic acid on the activity of betamethasone-17,21-dipropionate in the treatment of erythematous squamous dermatoses. J Int Med Res 1983; 11(2)108–12